Skip to content
ALKS·Nasdaq·US

Alkermes

Alkermes is a biopharmaceutical company focused on central nervous system disorders, including schizophrenia, bipolar I disorder, alcohol and opioid dependence, and narcolepsy. It generates revenue primarily from proprietary product sales and also from manufacturing and royalty arrangements tied to partnered medicines.

Recent Activity

Updated Sep 24, 2026
–Alkermes reported results demonstrating proof-of-concept for its orexin drug in ADHD, heightening anticipation for a coming readout in 2027.

Past updates are part of the Pro plan.

Thematic Position

ALKS

Relationship Groups

Suppliers4
Customers6
Partners1
Licensing3
Competitors11

Relationship details are part of the Pro plan.

Ended Relationships

10 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

tarifftrade restriction
U.S. and foreign government tariffs since April 2025 impact Alkermes supply chain and revenues
SEC 10-KFeb 25, 2026

The full regulatory passage is part of the Pro plan.

15 more · Regulatory and geopolitical insights are part of the Pro plan.

Disclosed customers above 10% of revenue

3 customers · Named major customers are part of the Pro plan.